• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug-Device Combinations

Pear Therapeutics closes $80M Series D

December 9, 2020 By Sean Whooley

Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Novartis, opioids, peartherapeutics

Canada approves Abbott Freestyle Libre 2 for adults and children

December 3, 2020 By Sean Whooley

Abbott (NYSE:ABT) announced that Health Canada has approved its FreeStyle Libre 2 continuous glucose monitor for adults and children. The next-generation, wearable, sensor-based CGM technology with real-time alarms is approved for use in adults and children (four years old and up) and will be priced the same as the current FreeStyle Libre system, according to a […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance Tagged With: abbott, Health Canada

BD to put $1.2B into drug-delivery plant expansions

December 2, 2020 By Sean Whooley

Becton Dickinson (NYSE:BDX) announced today that it plans to invest $1.2 billion to expand and upgrade multiple drug-delivery facilities. Franklin Lakes, N.J.-based BD plans to invest the $1.2 billion over a four-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug-delivery systems (ADDS) across its six global manufacturing locations, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Becton Dickinson

Appeals court nixes GSK’s petition for new trial in Vectura patent spat

November 20, 2020 By Nancy Crotti

The Federal Circuit Court has rejected Glaxo Smith Kline’s (NYSE:GSK) petition for a new trial in a patent case brought by British inhaler company Vectura. The circuit court upheld a May 2019 jury verdict in U.S. District Court for the District of Delaware, awarding Ventura $89.7 million damages for the period from August 2016 through […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Respiratory Tagged With: GlaxoSmithKline plc, Vectura

Lilly and Ypsomed team up on automated insulin delivery

November 19, 2020 By Brian Buntz

Eli Lilly

Eli Lilly (NYSE:LLY) and Ypsomed (SWX:YPSN) are teaming up to create an automated insulin delivery system. Lilly would commercialize the device, which would incorporate an insulin pump from Ypsomed. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016. Now available in 21 countries, the pump includes a touch screen. Lilly plans on commercializing […]

Filed Under: Diabetes, Drug-Device Combinations Tagged With: Eli Lilly & Co., Novo Nordisk, Ypsomed, YpsoPump

Alaris remediation could cost BD up to $244M

November 18, 2020 By Chris Newmarker

BD-logo-new

Becton Dickinson (NYSE:BDX) in its most recent fiscal year set aside $244 million to cover future product remediation costs, including the company’s work to fix its problematic Alaris infusion pumps. The Franklin Lakes, N.J.–based company has had shipments of the pumps on hold since early this year, when FDA called for a comprehensive 510(k) submission to […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls Tagged With: BD, Becton Dickinson

Brooklyn spending $500K on BioBAT research and manufacturing space

November 17, 2020 By Sean Whooley

SUNY Downstate Health Sciences University announced that it received a $500,000 capital fund grant from Brooklyn to construct a research space. Brooklyn Borough President Eric Adams awarded the grant to SUNY to construct a state-of-the-art biotechnology research and manufacturing space at BioBAT, a nonprofit organization seeking to grow the biotechnology industry in New York City. […]

Filed Under: Business/Financial News, Discovery, Drug-Device Combinations, Featured, Funding Roundup Tagged With: BioBAT, SUNY Downstate

Baxter lands major DoD contract

November 13, 2020 By Sean Whooley

Baxter

The U.S. Defense Dept. (DoD) announced that it awarded Baxter (NYSE:BAX) $40 million for its infusion pumps and accessories. Baxter’s contract includes a maximum $40 million fixed-price award with economic-price-adjustment and indefinite-delivery/indefinite-quantity for its infusion pumps and accessories. The competitive acquisition had 105 offers received. The five-year contract has no option periods with the location being […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Baxter, U.S. Defense Dept.

Baxter wins Canadian clearance for infusion system

November 12, 2020 By Sean Whooley

Baxter

Baxter (NYSE:BAX) Canada announced today that it received Health Canada authorization for its Novum IQ infusion platform. Novum IQ received marketing authorization for its large volume pump and syringe infusion pumps, as well as Mississauga, Ontario-based Baxter Canada’s Dose IQ safety software. Baxter expects Novum IQ to be available to Canadian customers in the coming weeks, […]

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance Tagged With: Baxter, Health Canada

Teva Pharmaceuticals’ stock sinks 6.5% on Q3 results

November 5, 2020 By Brian Buntz

Teva

Teva (NYSE: TEVA) reported third-quarter results today that matched analysts’ consensus forecast. The company will maintain its guidance for the rest of the year. Teva, which has dual headquarters in Israel and Parsippany, N.J., reported a loss of -$4.3 billion or -$3.97 per share on revenue of $3.9 billion for the quarter ended September 30, […]

Filed Under: Drug-Device Combinations, mHealth (Mobile Health), Pharmaceuticals, Wall Street Beat Tagged With: COVID-19, Kare Schultz, Teva

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 190
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS